Suppression of early pro-inflammatory senescent signature post-radiotherapy mitigates chronic bone damage
Preprint
Abstract
Cellular senescence has been implicated in the pathophysiology of radiotherapy-related bone loss. Based on our previous work, clearance of senescent cells using genetic and pharmacological tools alleviates the anomalies associated with radiation-associated bone deterioration. The pro-inflammatory senescence associated secretome referred to as senescence associated secretory phenotype (SASP), is a hallmark of cellular senescence. The modulation of SASP by senomorphic drugs, potentially can suppress the pro-inflammatory secretome of senescent cells, irrespective of the underlying senescence mechanism. In this study we tested a senomorphic drug, ruxolitinib, a Janus kinase inhibitor (JAKi), during acute and chronic radiotherapy related effects on the bone. Our clinical data indicate an early increase in several pro-inflammatory SASP proteins following radiotherapy of spinal metastasis in prostate cancer patients. Longitudinal assessment of SASP-related genes confirmed this acute elevation in several SASP markers in systemic circulation following irradiation of mouse femurs. In a proof-of-concept study, following two preclinical radiotherapy regimens of cumulative doses of 30Gy (5 x 6Gy) and 60Gy (5 x 12Gy), a senomorphic approach of JAKi treatment was more effective in alleviating radiation-related bone loss compared to the senolytic cocktail of D+Q. Early and intermittent suppression of SASP using JAK inhibitors alleviated chronic bone deterioration, diminished telomere dysfunction, lowered senescence and SASP marker expression, reduced bone-marrow adiposity, and mitigated radiation related lymphatic impairment. Overall, our study shows that early targeting of SASP proteins could be a potential therapeutic to prevent radiotherapy-related chronic bone loss and risk of fractures. Lay Summary: Radiotherapy as part of cancer treatment is correlated with an acute increase in senescent cells. Here we show that the pro-inflammatory senescence associated secretory phenotype (SASP) becomes much more prominent soon after radiotherapy in both patients and mice. Suppression of the SASP using a Janus kinase inhibitor, ruxolitinib, reduced the overall senescent cell burden, improved bone architecture by promoting bone formation, reduced bone marrow adiposity, and mitigated radiation-induced lymphatic impairment. Overall, these findings suggest that early inhibition of the SASP may help mitigate several bone anomalies and prevent long-term bone loss and fractures after radiotherapy. GraphicalKeywords
Funding Information
- NIH (AG082681)
- NIH (AG062413)
- NIH (AG086085)
- NIH (AG076515)
- NIH (K12 CA90628-23)
- NIH (AG R01055529)
This publication has 46 references indexed in Scilit:
- Bone Marrow Adiposity in Models of Radiation- and Aging-Related Bone Loss Is Dependent on Cellular SenescenceJournal of Bone and Mineral Research, 2022
- Development and Assessment of a Predictive Score for Vertebral Compression Fracture After Stereotactic Body Radiation Therapy for Spinal MetastasesJAMA Oncology, 2022
- Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate CancerJAMA Oncology, 2021
- Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone LossJournal of Bone and Mineral Research, 2020
- Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct MechanismsJournal of Bone and Mineral Research, 2016
- Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicityStrahlentherapie und Onkologie, 2015
- Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature CommitteeJournal of Bone and Mineral Research, 2012
- Risk of Pelvic Fractures in Older Women Following Pelvic IrradiationJAMA, 2005
- The effect of X-rays on bone: a pictorial reviewEuropean Radiology, 2005
- Changes in Telomerase Activity and Telomere Length during Human T Lymphocyte SenescenceExperimental Cell Research, 1997